4 Months on Semaglutide: Biopsy Finds Immune Cells Where They Don’t Belong
When Stomach Medicine Triggers a Rare Reaction: Understanding GLP-1 Drugs and Eosinophilic Gastroenteritis
In simple terms: A woman taking a popular diabetes/weight-loss drug developed a rare stomach condition. When she stopped the drug, she got better. Scientists are now paying attention.
The Case That Got Doctors Talking
A 57-year-old woman with type 2 diabetes had been taking semaglutide (the active ingredient in drugs like Ozempic® and Wegovy®). Over four months, she developed:
- Persistent upper stomach pain (epigastric pain)
- Loss of appetite
- Unintended weight loss
Her blood tests showed markedly high eosinophils (a type of white blood cell). Stomach and intestine biopsies confirmed eosinophilic gastroenteritis—a rare condition where these cells build up in the digestive tract lining.
Published in: International Journal of Research in Medical Sciences (August 2026)
Hospital: Security Forces Hospital, Makkah, Saudi Arabia
Lead author: Abrar A. Oraijah
Gastroenterologist: Mansour Alghamdi
What Is Eosinophilic Gastroenteritis? (ELI5)
Imagine your digestive tract is a house. Eosinophils are like specialized security guards normally deployed to fight parasites or handle allergic reactions.
In eosinophilic gastroenteritis, these guards show up in the wrong place (the walls of your stomach/intestines) and cause inflammation—like security guards tearing up the carpet because they think there’s a threat.
Symptoms are vague and frustrating:
- Abdominal pain
- Nausea
- Poor appetite
- Sometimes blockages
How Doctors Ruled Out Other Causes
Before blaming the drug, the medical team investigated the "usual suspects":
- Parasitic infections (most common cause worldwide) Ruled out
- Allergic diseases Ruled out
- Blood cancers Ruled out
What remained? The timing—the symptoms started while she was on semaglutide.
Why this matters: Ruling out parasites and other causes turns a "coincidence" into something worth publishing.
The Strongest Clue: What Happened After Stopping the Drug
This is called a "dechallenge"—stopping a drug to see if the problem reverses.
| Timeline | What Happened |
|---|---|
| On semaglutide | Pain, high eosinophils, abnormal biopsies |
| Drug stopped | Symptoms resolved over months |
| Blood retested | Eosinophil count returned to normal |
| Repeat biopsies | Tissue healed completely (histological resolution) |
Why this is important: The problem didn’t just "feel better"—it healed at the tissue level.
But it’s not proof: No one restarted the drug (rechallenge) because that would be unethical. A single case can’t rule out that the illness might have resolved on its own.
What Big Data Shows: The Danish Registry Study
Researchers at the University of Southern Denmark analyzed nationwide health records (2015–2024):
- Method: Sequence symmetry analysis (compares each person to themselves before/after starting a drug)
- Drugs studied: GLP-1 drugs vs. SGLT2 inhibitors vs. DPP-4 inhibitors
- Finding: Hypereosinophilia (very high eosinophils) was ~3× more likely after starting a GLP-1 drug
- Specific to semaglutide: Same signal held up
- Comparator drugs: No such signal
Study design strength: Self-controlled (removes many confounding factors)
Limitation: Measures a lab abnormality, not a diagnosed disease
Other Similar Cases Around the World
Over ~3 years, scattered reports have appeared across multiple organs:
| Location | Organ Affected | Details |
|---|---|---|
| Cali, Colombia | Fascia (connective tissue) | 42F developed eosinophilic fasciitis; needed strong immune therapy |
| Monterrey, Mexico | Esophagus | 46M had trouble swallowing; food stuck 40cm down |
| Belgium | Duodenum (small intestine) | Presenting as bowel obstruction |
| Conference abstract | Colon | First reported case of semaglutide-associated eosinophilic colitis |
Pattern: Fascia, esophagus, duodenum, stomach, colon—different locations, same mechanism
Proposed explanation: Drug-induced hypersensitivity reaction (immune system overreacting to the drug) — not the usual slowed digestion causing typical GLP-1 nausea.
How Rare Is This Really?
Let’s put it in perspective:
- ~1 in 8 U.S. adults currently take a GLP-1 drug (KFF polling)
- FDA adverse event database: 81,752 total reports for GLP-1 class
- GI toxicity reports: 21,281 (mostly nausea, vomiting, diarrhea, constipation)
- Eosinophilic disease reports: A handful worldwide
Bottom line: These complications are vanishingly rare compared to the millions of prescriptions.
What Patients Should Actually Do
For Doctors (from the study authors):
"Higher index of suspicion" when someone on a GLP-1 drug has persistent or atypical GI symptoms — because early detection + stopping the drug = complete recovery.
For Patients: Know the Difference
| Typical GLP-1 Side Effects (Expected, Usually Temporary) | Red Flags (Worth Reporting) |
|---|---|
| Nausea in first weeks after starting/increasing dose | Pain lasting months, not weeks |
| Eases over time | Appetite loss that doesn’t improve |
| Manageable with dose adjustments | Unexplained weight loss beyond drug effect |
| New difficulty swallowing | |
| Symptoms that don’t match the usual pattern |
Important Points Callout
DO NOT STOP YOUR MEDICATION BASED ON THIS ARTICLE
- GLP-1 drugs have proven benefits for blood sugar, weight, and heart health
- Eosinophilic complications are rare and appear reversible on withdrawal
- Talk to your prescriber if you have concerning symptoms
- A simple blood count (CBC with differential) is inexpensive and can check eosinophils
- Unexplained high eosinophils deserve a next question—not a shrug
Summary
- A rare but real signal: A handful of case reports + one large registry study suggest GLP-1 drugs may trigger eosinophilic inflammation in the digestive tract (and rarely other organs).
- Mechanism differs from typical side effects: This appears to be an immune hypersensitivity reaction, not the slowed stomach emptying that causes usual nausea.
- Reversible with early action: In reported cases, stopping the drug led to complete recovery—symptoms, blood counts, and tissue biopsies all normalized.
- Context matters: These cases are extremely rare against millions of prescriptions. Typical GI side effects (nausea, diarrhea) remain far more common.
- Practical takeaway: If you’re on a GLP-1 drug and develop persistent, atypical symptoms (months of pain, trouble swallowing, unexplained weight loss), tell your doctor. A simple blood test can check eosinophils.
FAQ
1. Does this prove semaglutide causes eosinophilic gastroenteritis?
No. A single case report cannot prove causation. The strongest evidence is that everything normalized after stopping the drug (dechallenge), but no one restarted it (rechallenge) for ethical reasons. The Danish registry study adds supporting evidence but measures lab abnormalities, not confirmed disease.
2. How common is this side effect?
Extremely rare. Only a handful of cases have been published globally despite millions of prescriptions. Typical GI side effects (nausea, vomiting, diarrhea, constipation) are vastly more common.
3. What symptoms should I watch for and report to my doctor?
- Stomach pain lasting months (not the first few weeks)
- Loss of appetite that doesn’t improve
- Weight loss beyond what the drug should cause
- New difficulty swallowing
- Symptoms that feel different from typical GLP-1 nausea
4. Should I stop taking my GLP-1 medication?
No—never stop a prescribed medication without talking to your doctor. These drugs have documented benefits for diabetes, weight, and cardiovascular health. Stopping abruptly carries its own risks. Discuss any concerns with your prescriber.
5. What test can check for this?
A routine blood test called a CBC with differential (complete blood count with white blood cell breakdown) measures eosinophil levels. It’s inexpensive and widely available. If eosinophils are high without a clear cause (like parasites or allergies), your doctor can investigate further.